Skip to main content
. 2022 Jun 6;2(6):402–416. doi: 10.1158/2767-9764.CRC-22-0124

FIGURE 4.

FIGURE 4

Chronic SMOi treatment reduces specific HAT and HDAC protein levels in SI-CSC medulloblastomas in vitro and in vivo. Western blot analyses of histone acetyl transferases and histone deacetylases in vehicle versus LDE225 -resistant fSmoM2;hGFAP-cre and Ptch;p53 SHH medulloblastomas. A and D,fSmoM2;hGFAP-cre SI-CSC, (B and E) Ptch;p53 SI-CSC medulloblastomas and (C and F) Ptch;p53 SD-CSC medulloblastomas. *ß-ACTIN loading control is the same as shown in Figs. 4C and F as the same blot was stripped and probed with multiple antibodies due to limited sample amounts. G, Western blot analyses of LDE225-resistant Ptch;p53 SI-CSC tumorsphere cells treated with LDE225 for long term (>2 weeks) in vitro show the same HAT and HDAC expression changes. H, Acute (24 hours) treatment of Ptch;p53 SI-CSC tumorsphere cells show no significant changes in CBP, GCN5, or HAT1 protein levels in response to short-term LDE225 treatment.